Loading
A phase 3 trial of FES PET in Breast cancer, run by Asan Medical Center, completed.
Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT01986569 by Asan Medical Center, with 93 participants recorded, started 2013-11 and reaching its primary completion in 2016-11. Interventions recorded: [18F]fluoroestradiol (FES). Conditions recorded: Recurrent Breast Cancer, Stage IV Breast Cancer.
Linked to the technology FES PET because the registry's title names it ("18f fluoroestradiol pet") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FES, FES PET (oestrogen receptor imaging), Breast cancer (all types) and the tag pipeline.
Shares FES, FES PET (oestrogen receptor imaging), Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/